ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,765 companies indexed · Last updated: today
DirectoryFinance & InsuranceHolding CompaniesZurichVeraxa Biotech AG
Veraxa Biotech AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Veraxa Biotech Holding AG develops antibody-based cancer therapeutics, including antibody–drug conjugates (ADCs) and BiTAC bispecific formats, and employs proprietary technologies such as droplet‑based functional antibody screening, genetic code expansion for positional conjugation, and bioorthogonal click chemistry. The company is advancing a proprietary oncology pipeline that includes ADC and BiTAC TCE programs, with the VX‑A901 program in clinical studies for AML.

AI-generated
Offering

Products & services

Industry:Holding Companies
✓ Offered6
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
3.8/5

Veraxa Biotech AG

BiTAC TCEs
Bi-targeted T-cell-engaging bispecific molecules with two complementary antibody precursors; CD3 binding is activated only upon co-localisation on tumour cells to reduce off-tumour toxicity.
ADC technologies
Antibody-drug-conjugate technologies with genetically precise conjugation-site positioning, efficient click chemistry and proprietary payloads for homogeneous, stable ADCs with improved pharmacokinetics.
Functional antibody screening
High-throughput droplet microfluidics with single-cell analysis to identify functional antibodies against various targets, including internalising as well as agonistic and antagonistic antibodies.
BiTAC platform
Antibody platform with two complementary precursors that only form the therapeutically active molecule upon simultaneous target binding on cancer cells, enabling selective activation.
Pipeline of novel antibody-based cancer therapeutics
Development of a clinical pipeline of novel oncology programmes, in particular BiTAC-TCEs, BsADCs, BiTAC-ADCs and monoclonal antibodies for AML, breast, lung, colon and pancreatic cancer.
Partnering
Strategic product partnerships and R&D alliances for antibody, ADC and target development; collaboration from target to ADC as well as access to screening and conjugation technologies.
Trust & reputation

ranQ Trust Score of Veraxa Biotech AG: 3.8 out of 5.0

Trust Score3.8/ 5.0

High

x

Data basis 58% · As of October 2026

Veraxa Biotech AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Veraxa Biotech AG scores 53.4 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.25.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Veraxa Biotech AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Veraxa Biotech AG scores 51.9 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.77.14%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.26.74%
Qualifications+0.00

Veraxa Biotech AG reaches a ranQ Trust Score of 3.8 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

July 1, 2026Media
Einschätzung: Erster Börsengang einer Beteiligung dürfte Xlife kräftig Schub geben
fuw.ch

Knowledge

No knowledge articles yet

Once Veraxa Biotech AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Veraxa Biotech AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Veraxa Biotech AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Veraxa Biotech AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Talacker 35
8001 Zurich

At a glance

Legal form
Corporation
UID
CHE-441.201.868
Founded
2025 · 1 year
Last commercial register change
July 30, 2026
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    UA
    Under Armour Global CH GmbH
    Zurich
    PD
    Pensionsstiftung der Stiftung Zürcher Blutspendedienst SRK
    Zurich
    NH
    Neurimmune Holding AG
    Schlieren
    AH
    Angst Holding AG
    Zurich
    TA
    Tectus AG
    Zurich
    BH
    Brust-Zentrum Holding AG
    Zurich
    UH
    u-blox Holding AG
    Thalwil
    EZ
    ETH Zürich SEC AG
    Zürich Eth-Zentrum